{"entity":{"id":"nct06212076","kind":"trial","name":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients","aka":[],"tldr":"A phase 1/2 trial of IPG1094 in advanced solid tumours, run by Nanjing Immunophage Biotech Co., Ltd, now recruiting.","summary":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients is a phase 1/2 interventional study registered as NCT06212076 by Nanjing Immunophage Biotech Co., Ltd, with 60 participants planned, started 2024-07-11 and due to reach its primary completion in 2027-07-09. Interventions recorded: IPG1094.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06212076","url":"https://clinicaltrials.gov/study/NCT06212076"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06212076","phase":"1/2","setting":"A Phase I/II, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Characteristics and Initial Anti-tumor Activity of IPG1094 in Patients With Advanced Solid Tumors","sponsor":"Nanjing Immunophage Biotech Co., Ltd","enrolled":60,"outcomes":[]},"route":"/trials/nct06212076/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"nanjing-immunophage-biotech","kind":"company","name":"Nanjing Immunophage Biotech","route":"/companies/nanjing-immunophage-biotech/"}],"drug":[{"id":"ipg1094","kind":"drug","name":"IPG1094","route":"/drugs/ipg1094/"}]}}